FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study)

Hideyuki Mishima; Koji Oba; Junichi Sakamoto; Kei Muro; Takayuki Yoshino; Ichinosuke Hyodo; Yoshihiko Maehara

doi:10.1093/jjco/hyr180

FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study)

Hideyuki Mishima, Koji Oba, Junichi Sakamoto, Kei Muro, Takayuki Yoshino, Ichinosuke Hyodo, Yoshihiko Maehara

Surgery

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

We planned a multicenter randomized phase III study to evaluate the efficacy of appropriate dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/metastatic colorectal cancer who have failed prior bevacizumab plus oxaliplatin-based therapy. The primary endpoint is progression-free survival. The secondary endpoints are the toxicity, response rate, time to treatment failure, overall survival, overall survival from the start of the first-line treatment and second progression-free survival (time duration from the initiation of the first-line treatment until progression after the protocol treatment). A total of 370 patients were considered to be appropriate for this trial.

Original language	English
Article number	hyr180
Pages (from-to)	134-138
Number of pages	5
Journal	Japanese journal of clinical oncology
Volume	42
Issue number	2
DOIs	https://doi.org/10.1093/jjco/hyr180
Publication status	Published - Feb 2012

All Science Journal Classification (ASJC) codes

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jjco/hyr180

Fingerprint

Dive into the research topics of 'FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study)'. Together they form a unique fingerprint.

Cite this

Mishima, H., Oba, K., Sakamoto, J., Muro, K., Yoshino, T., Hyodo, I., & Maehara, Y. (2012). FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study). Japanese journal of clinical oncology, 42(2), 134-138. Article hyr180. https://doi.org/10.1093/jjco/hyr180

FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study). / Mishima, Hideyuki; Oba, Koji; Sakamoto, Junichi et al.
In: Japanese journal of clinical oncology, Vol. 42, No. 2, hyr180, 02.2012, p. 134-138.

Research output: Contribution to journal › Article › peer-review

Mishima, H, Oba, K, Sakamoto, J, Muro, K, Yoshino, T, Hyodo, I & Maehara, Y 2012, 'FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study)', Japanese journal of clinical oncology, vol. 42, no. 2, hyr180, pp. 134-138. https://doi.org/10.1093/jjco/hyr180

Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I et al. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study). Japanese journal of clinical oncology. 2012 Feb;42(2):134-138. hyr180. doi: 10.1093/jjco/hyr180

Mishima, Hideyuki ; Oba, Koji ; Sakamoto, Junichi et al. / FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy : A randomized phase III study (EAGLE study). In: Japanese journal of clinical oncology. 2012 ; Vol. 42, No. 2. pp. 134-138.

@article{aad296dbb56245a2945f2e0fff52d96d,

title = "FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study)",

abstract = "We planned a multicenter randomized phase III study to evaluate the efficacy of appropriate dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/metastatic colorectal cancer who have failed prior bevacizumab plus oxaliplatin-based therapy. The primary endpoint is progression-free survival. The secondary endpoints are the toxicity, response rate, time to treatment failure, overall survival, overall survival from the start of the first-line treatment and second progression-free survival (time duration from the initiation of the first-line treatment until progression after the protocol treatment). A total of 370 patients were considered to be appropriate for this trial.",

author = "Hideyuki Mishima and Koji Oba and Junichi Sakamoto and Kei Muro and Takayuki Yoshino and Ichinosuke Hyodo and Yoshihiko Maehara",

year = "2012",

month = feb,

doi = "10.1093/jjco/hyr180",

language = "English",

volume = "42",

pages = "134--138",

journal = "Japanese journal of clinical oncology",

issn = "0368-2811",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy

T2 - A randomized phase III study (EAGLE study)

AU - Mishima, Hideyuki

AU - Oba, Koji

AU - Sakamoto, Junichi

AU - Muro, Kei

AU - Yoshino, Takayuki

AU - Hyodo, Ichinosuke

AU - Maehara, Yoshihiko

PY - 2012/2

Y1 - 2012/2

N2 - We planned a multicenter randomized phase III study to evaluate the efficacy of appropriate dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/metastatic colorectal cancer who have failed prior bevacizumab plus oxaliplatin-based therapy. The primary endpoint is progression-free survival. The secondary endpoints are the toxicity, response rate, time to treatment failure, overall survival, overall survival from the start of the first-line treatment and second progression-free survival (time duration from the initiation of the first-line treatment until progression after the protocol treatment). A total of 370 patients were considered to be appropriate for this trial.

AB - We planned a multicenter randomized phase III study to evaluate the efficacy of appropriate dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/metastatic colorectal cancer who have failed prior bevacizumab plus oxaliplatin-based therapy. The primary endpoint is progression-free survival. The secondary endpoints are the toxicity, response rate, time to treatment failure, overall survival, overall survival from the start of the first-line treatment and second progression-free survival (time duration from the initiation of the first-line treatment until progression after the protocol treatment). A total of 370 patients were considered to be appropriate for this trial.

UR - http://www.scopus.com/inward/record.url?scp=84856625485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856625485&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyr180

DO - 10.1093/jjco/hyr180

M3 - Article

C2 - 22167662

AN - SCOPUS:84856625485

SN - 0368-2811

VL - 42

SP - 134

EP - 138

JO - Japanese journal of clinical oncology

JF - Japanese journal of clinical oncology

IS - 2

M1 - hyr180

ER -

FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this